Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.34 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.33 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.32 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.31 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.31 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4269574 | 1.00 | TSHR (0.46) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL215571 | 1.00 | TSHR (0.46) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL769926 | 0.97 | — | — | |
| SCHEMBL215572 | 0.97 | — | — | |
| SCHEMBL4269578 | 0.97 | — | — | |
| SCHEMBL27315313 | 0.94 | TSHR (0.46) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL21612233 | 0.92 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL3926493 | 0.92 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| Methylene Chloride SCHEMBL28185523 | 0.91 | LMNA (0.40) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL28144996 | 0.89 | TSHR (0.37) | TSHRHCAR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105392-A | What a kind of tenofovir Chinese mugwort drew phenol amine efficiently synthesizes technique | 石家庄凯赛医药科技有限公司 | 2019-08-09 | — | — | CN | claimed |
| CN-106432328-B | A kind of preparation method of Suo Feibuwei intermediate | 江苏福瑞生物医药有限公司 | 2019-03-22 | — | — | CN | claimed |
| CN-109485675-A | Puerarin derivate and preparation method thereof and application | 福州热方健康科技有限公司 | 2019-03-19 | — | — | CN | claimed |
| CN-109467515-A | The synthetic method of intermediate l-Alanine isopropyl ester hydrochloride | 南京红杉生物科技有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-104761582-B | A method of preparing N- [(S)-(2,3,4,5,6- phenyl-pentafluorides oxygroup) phenoxy group phosphoryl]-l-Alanine isopropyl ester | 上海创诺医药集团有限公司 | 2018-09-28 | — | — | CN | claimed |
| CN-108409788-A | A kind of fumaric acid tenofovir Chinese mugwort draws the preparation method of phenol amine | 山东科兴生物制品有限公司 | 2018-08-17 | — | — | CN | claimed |
| CN-108409790-A | A kind of tenofovir Chinese mugwort draws the easy synthesis technology of phenol amine hemifumarate | 南京哈柏医药科技有限公司 | 2018-08-17 | — | — | CN | claimed |
| CN-108299500-A | A kind of fumaric acid tenofovir Chinese mugwort draws phenol amine bulk pharmaceutical chemicals and its production technology | 安徽安科恒益药业有限公司 | 2018-07-20 | — | — | CN | claimed |
| CN-107868105-A | A kind of preparation method of Suo Feibuwei key intermediates | 北京凯因科技股份有限公司 | 2018-04-03 | — | — | CN | claimed |
| CN-206467170-U | The double kettle cross backflow reaction systems of L alanine isopropyl esters hydrochloride | 苏利制药科技江阴有限公司 | 2017-09-05 | — | — | CN | claimed |
| CN-106977543-A | The preparation technology of improved Suo Feibuwei intermediates | 上海医药工业研究院 | 2017-07-25 | — | — | CN | claimed |
| US-9676803-B2 | Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine | CIPLA LIMITED (IN) | 2017-06-13 | — | — | US | claimed |
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2016-05-05 | — | — | US | claimed |
| CN-205188179-U | L - alanine isopropyl ester hydrochloric acid reaction dewatering system | SULI PHARMACEUTICAL TECH JIANGYIN CO LTD | 2016-04-27 | — | — | CN | claimed |
| EP-3004121-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL]METHOXY]PROPYL]ADENINE | Cipla Limited (IN) | 2016-04-13 | — | — | EP | claimed |
| CN-104610404-B | A kind of preparation method of ribofuranose phosphate derivative | Nantong Chang You medicine company Science and Technology Ltd. (CN) | 2016-04-06 | — | — | CN | claimed |
| CN-104761582-A | Method for preparation of N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxy phosphoryl]-L-alanine isopropyl ester | SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO LTD | 2015-07-08 | — | — | CN | claimed |
| CN-104610404-A | Preparation method of ribofuranose phosphate derivative | NANTONG CHANGYOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | claimed |
| CN-104230985-A | Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate | BEIJING THTD PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-12-24 | — | — | CN | claimed |
| WO-2014195724-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2014-12-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | MTAP, PARP9, APRT | CA2 3978/4885PPARG 4052/4885GRIN2D 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.